Homozygous HLA-DQA1*0102, -DQB1*0602, human CD4-transgenic Ab0 NOD mice (“HLA-DQ6.2 mice”; stock number 006023) were purchased from Jackson Laboratories, Bar Harbor, ME, USA, and bred at the University of Helsinki Laboratory Animal Centre17. All mice were housed under specific pathogen-free conditions, under a 14–10 h light–dark cycle, at 22 ± 2 °C and 50–60% humidity. Pandemrix vaccine was injected under isoflurane anesthesia into the right thigh muscle (50 μl emulsion volume; male or female mice; 3 months of age), followed by one booster injection after 14 days. After 6–9 weeks from the first injection, mice were exsanguinated by retro-orbital bleeding under ketamine/xylazine anesthesia (Intervet International, Boxmeer, The Netherlands; Bayer HealthCare, Leverkusen, Germany), and spleens were harvested for collection of cells.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.